相关实验视频
Updated: May 30, 2025

08:09
A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
Published on: June 7, 2018
9.7K
在使用心脏毒性抗癌疗法之前的风险评估 7 步骤
Jieli Tong1,2, Isabelle Senechal1, Sivatharshini Ramalingam1
1Cardio-Oncology Centre of Excellence, Royal Brompton Hospital, London, UK.
British journal of hospital medicine (London, England : 2005)
|January 25, 2025
概括
癌症患者的心血管疾病风险正在上升. 本综述为医生提供了七步指南,帮助医生在癌症治疗前评估心脏风险,帮助早期检测和个性化护理.
科学领域:
- 心脏瘤学 - 心脏瘤学
- 心血管医学 心血管医学
- 在瘤学瘤学.
背景情况:
- 心血管疾病 (CV) 和癌症治疗心脏毒性越来越令人担忧.
- 欧洲心脏病学会 (ESC) 2022年指南强调对心脏毒性进行标准化风险分层.
- 心力衰竭协会-国际心脏瘤学会 (HFA-ICOS) 的工具对于预治疗风险评估至关重要.
研究的目的:
- 总结一下瘤患者心脏风险分层的关键点.
- 为全科医生提供一个简单的7步指南.
- 帮助评估与潜在的心脏毒性瘤治疗相关的风险.
主要方法:
- 欧洲心脏病学会 (ESC) 2022年心脏瘤学指南的审查.
- 对心脏毒性的风险分层步骤的总结.
- 包括在接受特定疗法 (人环素,HER2向,BCR-ABL抑制剂) 的患者的验证数据.
主要成果:
- 基线CV风险评估可以早期识别心脏毒性.
- 分层化允许个性化的癌症治疗和监测.
- 心脏保护可以分配给高危人群.
结论:
- 对接受潜在心脏毒性癌症治疗的患者来说,对心脏风险评估有系统的方法至关重要.
- 这本7步指南有助于导航心脏风险评估.
- 积极的风险管理可以改善心脏瘤病患者的治疗结果.
相关概念视频
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
115
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
115
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Electron Transport Chain: Complex I and II
10.7K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
10.7K
Mutagenicity and Carcinogenicity
1.2K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.2K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Cancer Survival Analysis
324
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
324

